Infusion Treatment for Alzheimer’s Disease

Get in Touch Today

Introducing a Breakthrough: Alzheimer's Disease Treatment Now Available through Neurovations

Call NowEmail Now

Breaking Ground: Alzheimer's Infusions Offer Hope

Recent research and FDA approvals have finally given us a treatment that slows the progression of Alzheimer’s Disease. Neurovations and the Napa Pain Institute are set to pioneer a new era of hope by offering the only FDA approved, IV infusion treatment for Alzheimer’s Disease.

For 5 years, Dr. Eric Grigsby and Neurovations have been involved in clinical studies evaluating Alzheimer’s Disease treatments. Finally, in July 2023, the U.S. Federal Drug Administration (FDA) approved one such treatment, named Leqembi, for the treatment of Alzheimer’s disease. Data from the clinical studies, presented to the FDA, demonstrate a significant reduction in the pace of progression of Alzheimer’s.

How are Alzheimer’s Disease Treatments administered?

Leqembi is administered every two weeks through an IV infusion, lasting a little more than an hour for each treatment. Infusions will be administered at our infusion suite in Napa, at Napa Pain Institute. Patients in the clinical study took the drug for 18 months, and we expect you will take the drug for at least 12 months.

Are Alzheimer’s Disease infusions Covered by insurance?

Medicare now covers the treatment for all patients with confirmed mild cognitive impairment or mild dementia showing the signs of Alzheimer’s Disease. It is required to have a PET scan, to see the typical brain changes of Alzheimer’s Disease, before you are eligible for Leqembi. The treatments will be covered under the same co-pay and deductible rules applied to other Medicare treatments. Private insurance plans are likely to offer coverage for Alzheimer’s infusions soon.

We take pride in assisting our patients in navigating the best coverage options for their care and can answer insurance questions you may have.

What is Leqembi?

Leqembi is the first drug to receive approval through the FDA’s Accelerated Approval pathway. This pathway indicates that clinical trials provided sufficient evidence of the drug meeting its primary objectives. These objectives include a statistically significant reduction in brain amyloid plaque. During the clinical trial, patients experienced a notable delay in cognitive decline by 5.3 months compared to those on a placebo after 18 months of treatment.

Side effects of Leqembi include changes in the brain, seen on MRI, including microscopic bleeding and microscopic swelling of certain areas of the brain which usually goes way over time. Other side effects and risks can be reviewed with your Doctor prior to the infusion.

Leqembi is specifically approved for individuals in the early stages of Alzheimer’s progression. By undergoing treatment, those exhibiting signs of the disease may gain more quality time with their families, maintain independence for a more extended period, and experience an enhanced quality of life.

Additional Resources

While the Napa Pain Institute specializes in pain management, there are numerous resources available specifically for Alzheimer’s disease within the broader medical community. 

Neurovations Research offers studies investigating different solutions for Alzheimer’s Disease.   

Neurovations Research

Community-based organizations and non-profits also play a vital role in offering assistance and resources, ranging from caregiver support services to educational workshops:

Alzheimer’s Association: 

Help and Support

Alzheimer’s and Dementia

Community Health Napa Valley

Alzheimer’s Services

Get in Touch Today

Introducing a Breakthrough: Alzheimer's Disease Treatment Now Available through Neurovations

Call NowEmail Now

This website uses cookies to ensure you get the best experience.


Dr. Johansson comes to us as a fellowship-trained and board-certified pain management specialist with nearly a decade of experience. She completed her fellowship training at Walter Reed National Military Medical Center in Bethesda, MD where she then became the associate program director of the pain medicine fellowship and an assistant professor of military and emergency medicine. She graduated from the Virginia Commonwealth University School of Medicine in Richmond, Virginia, was Pre-medicine at San Diego State University, and received her BSN from Marquette University in Milwaukee, Wisconsin.

Her breadth of experience comes from a full career of serving in the United States Navy where she was the recipient of multiple academic and military service awards including a Meritorious Service Medal, three Navy Commendation Medals, and numerous other individual, unit, and campaign awards. She has multiple published works and is the founding member of a military Pain Medicine Special Interest Group with the American Society of Regional Anesthesia.

In her free time, Dr. Johansson enjoys traveling, is newly married, loves dogs, and enjoys cooking and baking, as well as other creative pursuits. She has a particular interest in advanced procedural techniques for chronic pain relief and the effects of lifestyle on pain and healing. She looks forward to continuing our mission of providing our patients with the best care, every day.

Eric Grigsby, MD, MBA

CEO & Founder of Neurovations

Dr. Eric Grigsby enjoys a national reputation for excellence in the field of Pain Management. He has a background as a researcher, teacher and clinician and brings over 30 years of clinical experience to the Napa Pain Institute. Dr. Grigsby attended elementary and secondary school in his hometown of Knoxville, Tennessee, and received a Bachelor’s Degree in Biology and Economics from Brown University in Providence, Rhode Island. He formed an interest in Pain Management as a career while working at Boston Children’s Hospital in the Department of Orthopedic Surgery.

After graduating from Boston University Medical School in 1984, Dr. Grigsby trained in General Surgery, Anesthesiology, and Pain Management at the Mayo Clinic in Rochester, Minnesota. He was invited to join the Medical Staff and teach at the Mayo Medical School until moving to California in 1989. The Dean of the University of California at Davis Medical Center then invited Dr. Grigsby to establish their first Pain Management Center, where he served as Medical Director until 1992. Following his post at UC Davis, Dr. Grigsby established his private Pain Management practice in Napa, California.

Today, he and his staff of over 50 professionals consult with patients throughout Northern California and the western United States.  More recently, Dr Grigsby completed his Masters in Business Administration from Duke University’s Fuqua School of Business. He speaks nationally on topics such as non-operative treatment of spinal disorders, the safe use of medications for the treatment of pain, and the legal and regulatory issues relating to the proper treatment of patients with chronic illness.